blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP2505586

EP2505586 - INDOLE COMPOUND AND PHARMACEUTICAL USE THEREOF [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  06.01.2017
Database last updated on 29.10.2024
Most recent event   Tooltip06.01.2017No opposition filed within time limitpublished on 08.02.2017  [2017/06]
Applicant(s)For all designated states
Japan Tobacco, Inc.
2-1, Toranomon 2-chome
Minato-ku
Tokyo 105-8422 / JP
[N/P]
Former [2012/40]For all designated states
Japan Tobacco, Inc.
2-1, Toranomon 2-chome Minato-ku
Tokyo 105-8422 / JP
Inventor(s)01 / INOUE, Teruhiko
c/o Central Pharmaceutical Research Institute of
Japan Tobacco Inc.
1-1, Murasaki-cho
Takatsuki-shi Osaka 569-1125 / JP
02 / KAYA, Tetsudo
c/o Central Pharmaceutical Research Institute of
Japan Tobacco Inc.
1-1, Murasaki-cho
Takatsuki-shi Osaka 569-1125 / JP
03 / KIKUCHI, Shinichi
c/o Central Pharmaceutical Research Institute of
Japan Tobacco Inc.
1-1, Murasaki-cho
Takatsuki-shi Osaka 569-1125 / JP
04 / MATSUMURA, Koji
c/o Central Pharmaceutical Research Institute of
Japan Tobacco Inc.
1-1, Murasaki-cho
Takatsuki-shi Osaka 569-1125 / JP
05 / MASUO, Ritsuki
c/o Central Pharmaceutical Research Institute of
Japan Tobacco Inc.
1-1, Murasaki-cho
Takatsuki-shi Osaka 569-1125 / JP
06 / SUZUKI, Motoya
c/o Central Pharmaceutical Research Institute of
Japan Tobacco Inc.
1-1, Murasaki-cho
Takatsuki-shi Osaka 569-1125 / JP
07 / MAEKAWA, Michihide
c/o Central Pharmaceutical Research Institute of
Japan Tobacco Inc.
1-1, Murasaki-cho
Takatsuki-shi Osaka 569-1125 / JP
 [2012/40]
Representative(s)Vossius & Partner Patentanwälte Rechtsanwälte mbB
Siebertstrasse 3
81675 München / DE
[2016/09]
Former [2012/40]Harmsen, Dirk
Vossius & Partner Siebertstrasse 4
81675 München / DE
Application number, filing date10833248.725.11.2010
[2016/09]
WO2010JP70988
Priority number, dateJP2009026804025.11.2009         Original published format: JP 2009268040
[2012/40]
Filing languageJA
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2011065402
Date:03.06.2011
Language:JA
[2011/22]
Type: A1 Application with search report 
No.:EP2505586
Date:03.10.2012
Language:EN
[2012/40]
Type: B1 Patent specification 
No.:EP2505586
Date:02.03.2016
Language:EN
[2016/09]
Search report(s)International search report - published on:JP03.06.2011
(Supplementary) European search report - dispatched on:EP17.04.2013
ClassificationIPC:C07D401/14, A61K31/416, A61K31/4178, A61K31/422, A61K31/427, A61K31/433, A61K31/437, A61K31/4439, A61K31/454, A61K31/496, A61K31/5377, A61K31/55, A61P29/00, A61P37/02, A61P37/06, A61P37/08, A61P43/00, C07D403/04, C07D403/14, C07D405/14
[2012/40]
CPC:
C07D403/04 (EP,KR,US); A61K31/404 (KR); A61K31/416 (KR);
A61K31/5377 (KR); C07D401/14 (KR,US); C07D403/14 (KR,US);
C07D405/14 (KR,US); C07D413/14 (KR,US); C07D417/14 (KR,US);
C07D471/04 (KR,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2012/40]
Extension statesBA15.06.2012
ME15.06.2012
TitleGerman:INDOLVERBINDUNG UND IHRE PHARMAZEUTISCHE VERWENDUNG[2012/40]
English:INDOLE COMPOUND AND PHARMACEUTICAL USE THEREOF[2012/40]
French:COMPOSÉ D'INDOLE ET UTILISATION PHARMACEUTIQUE DE CELUI-CI[2012/40]
Entry into regional phase15.06.2012Translation filed 
15.06.2012National basic fee paid 
15.06.2012Search fee paid 
15.06.2012Designation fee(s) paid 
15.06.2012Examination fee paid 
Examination procedure15.06.2012Examination requested  [2012/40]
12.11.2013Amendment by applicant (claims and/or description)
17.03.2014Despatch of a communication from the examining division (Time limit: M02)
26.05.2014Reply to a communication from the examining division
15.07.2014Communication of intention to grant the patent
25.11.2014Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
20.01.2015Communication of intention to grant the patent
28.05.2015Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
22.06.2015Communication of intention to grant the patent
09.12.2015Fee for grant paid
09.12.2015Fee for publishing/printing paid
17.12.2015Information about intention to grant a patent
17.12.2015Receipt of the translation of the claim(s)
Divisional application(s)EP16158053.5  / EP3059234
EP20189306.2  / EP3766877
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  17.03.2014
Opposition(s)05.12.2016No opposition filed within time limit [2017/06]
Fees paidRenewal fee
23.11.2012Renewal fee patent year 03
25.11.2013Renewal fee patent year 04
24.11.2014Renewal fee patent year 05
25.11.2015Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[A]US2007254937  (JURCAK JOHN G [US], et al) [A] 1-26 * claims 1, 17 *;
 [A]US2007293499  (FLYNN GARY A [US], et al) [A] 1-26* claims 6-23 *
International search[Y]JP2003231687  (JAPAN TOBACCO INC);
 [A]WO2007076228  (BOEHRINGER INGELHEIM INT [DE], et al);
 [A]WO2007088401  (MERCK SHARP & DOHME [GB], et al);
 [Y]WO2008135785  (ASTRAZENECA AB [SE], et al)
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.